

Services & Capabilities

At Cerba Research, we offer a broad range of clinical support solutions.

Responds to Treatment

Immunophenotyping and target presence, MRD assesment, and phoresis for multiple myeloma changes

Patient Stratification

Patient stratification and inclusion & exclusion, primarily by sequencing and IHC/ISH

Immunogenicity/ADA

Detection anti-drug bodies by ELISA and functional immunogenicity tests













PK-PD

PD/RO by flow cytometry, PK of free circulating moAB drugs by ELISA, immune modulator PK by LC-MS


Biomarkers

Cellular biomarkers, soluble biomarkers & drug interference, exploratory analyses, and sequencing

Immune Monitoring

Behavior immune cells, quantification of cytokines & chemokines, and assessment immune responsiveness

Oncology Clinical Trial Phases



Our oncology trials are... 50% hemato-oncology 50% solid tumors

Global Experience



~20.000 SUBJECTS




59 COUNTRIES



5.000

Clinical Trials at Cerba Research*



Participating Countries



